Published in JAMA on April 12, 1995
Observational Trial on Cytokine Adsorption in Sepsis (OuTCASt) | NCT04306419
Pathophysiology of sepsis. Am J Pathol (2007) 3.19
Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford) (2010) 3.04
The pathogenesis of sepsis. Annu Rev Pathol (2011) 2.55
Balance of inflammatory cytokines related to severity and mortality of murine sepsis. Infect Immun (1996) 2.43
Passive immunity in prevention and treatment of infectious diseases. Clin Microbiol Rev (2000) 2.38
The epidemiology of severe sepsis in England, Wales and Northern Ireland, 1996 to 2004: secondary analysis of a high quality clinical database, the ICNARC Case Mix Programme Database. Crit Care (2006) 2.21
Antiendotoxin activity of cationic peptide antimicrobial agents. Infect Immun (1996) 2.13
The late phase of sepsis is characterized by an increased microbiological burden and death rate. Crit Care (2011) 1.77
Sepsis: multiple abnormalities, heterogeneous responses, and evolving understanding. Physiol Rev (2013) 1.72
Clinical practice guidelines for hospital-acquired pneumonia and ventilator-associated pneumonia in adults. Can J Infect Dis Med Microbiol (2008) 1.68
Suppression of proinflammatory cytokines in monocytes by a tetravalent guanylhydrazone. J Exp Med (1996) 1.61
Reducing mortality in sepsis: new directions. Crit Care (2002) 1.52
Immunoparalysis and adverse outcomes from critical illness. Pediatr Clin North Am (2008) 1.47
Modeling sepsis in the laboratory: merging sound science with animal well-being. Comp Med (2008) 1.42
Antitumor necrosis factor therapy is associated with improved survival in clinical sepsis trials: a meta-analysis. Crit Care Med (2013) 1.42
Therapeutic potential of HMGB1-targeting agents in sepsis. Expert Rev Mol Med (2008) 1.30
Novel HMGB1-inhibiting therapeutic agents for experimental sepsis. Shock (2009) 1.29
Shedding kinetics of soluble tumor necrosis factor (TNF) receptors after systemic TNF leaking during isolated limb perfusion. Relevance to the pathophysiology of septic shock. J Clin Invest (1998) 1.24
Corticotropin-releasing hormone augments proinflammatory cytokine production from macrophages in vitro and in lipopolysaccharide-induced endotoxin shock in mice. Infect Immun (2002) 1.22
Animal models of sepsis. Virulence (2013) 1.22
Advances in the management of sepsis and the understanding of key immunologic defects. Anesthesiology (2011) 1.21
ROS-induced ATF3 causes susceptibility to secondary infections during sepsis-associated immunosuppression. Nat Med (2011) 1.21
The level of lipopolysaccharide-binding protein is significantly increased in plasma in patients with the systemic inflammatory response syndrome. Clin Diagn Lab Immunol (1997) 1.14
Selective iNOS inhibition for the treatment of sepsis-induced acute kidney injury. Nat Rev Nephrol (2009) 1.14
Pharmacotherapy of acute lung injury and acute respiratory distress syndrome. Curr Med Chem (2008) 1.13
Systemic inflammatory response syndrome (SIRS): where did it come from and is it still relevant today? Virulence (2013) 1.10
Microparticles: markers and mediators of sepsis-induced microvascular dysfunction, immunosuppression, and AKI. Kidney Int (2015) 1.09
The inflammatory cytokines. New developments in the pathophysiology and treatment of septic shock. Drugs (1996) 1.07
Baicalin improves survival in a murine model of polymicrobial sepsis via suppressing inflammatory response and lymphocyte apoptosis. PLoS One (2012) 1.05
Surfactant therapy for acute lung injury and acute respiratory distress syndrome. Crit Care Clin (2011) 1.04
An alternative pathway for preclinical research in fluid management. Crit Care (2000) 1.03
The role of the intestine in the pathophysiology and management of severe acute pancreatitis. HPB (Oxford) (2003) 1.01
Lipopolysaccharide-induced cytokine cascade and lethality in LT alpha/TNF alpha-deficient mice. Mol Med (1997) 1.01
Molecular mechanism underlying the suppression of lipid oxidation during endotoxemia. Mol Immunol (2009) 1.00
Primary and secondary peritonitis: an update. Eur J Clin Microbiol Infect Dis (1998) 0.99
Targeting HMGB1 in the treatment of sepsis. Expert Opin Ther Targets (2014) 0.99
Myocardial dysfunction in sepsis: a large, unsolved puzzle. Crit Care Res Pract (2012) 0.97
The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial. Crit Care (2013) 0.96
Selective inhibition of intra-alveolar p55 TNF receptor attenuates ventilator-induced lung injury. Thorax (2011) 0.95
Cell-based therapy for acute organ injury: preclinical evidence and ongoing clinical trials using mesenchymal stem cells. Anesthesiology (2014) 0.94
Molecular mechanism and therapeutic modulation of high mobility group box 1 release and action: an updated review. Expert Rev Clin Immunol (2014) 0.94
Lack of evidence for qualitative treatment by disease severity interactions in clinical studies of severe sepsis. Crit Care (2005) 0.93
High mobility group box 1 protein as a potential drug target for infection- and injury-elicited inflammation. Inflamm Allergy Drug Targets (2010) 0.92
Nonredundant protective properties of FPR2/ALX in polymicrobial murine sepsis. Proc Natl Acad Sci U S A (2014) 0.91
Stem cells in sepsis and acute lung injury. Crit Care Med (2010) 0.90
Curcumin modulates leukocyte and platelet adhesion in murine sepsis. Microcirculation (2010) 0.89
Sepsis-induced myocardial dysfunction: pathophysiology and management. J Intensive Care (2016) 0.89
Chemokine C10 promotes disease resolution and survival in an experimental model of bacterial sepsis. Infect Immun (2000) 0.88
Effects of propofol on early and late cytokines in lipopolysaccharide-induced septic shock in rats. J Biomed Res (2010) 0.88
Induction of adrenomedullin mRNA and protein by lipopolysaccharide and paclitaxel (Taxol) in murine macrophages. Infect Immun (1998) 0.87
Review of experimental animal models of biliary acute pancreatitis and recent advances in basic research. HPB (Oxford) (2012) 0.87
Anti-endotoxin vaccines: back to the future. Virulence (2013) 0.86
Fingerprinting of the TLR4-induced acute inflammatory response. Exp Mol Pathol (2012) 0.86
A novel ligand-independent peptide inhibitor of TREM-1 suppresses tumor growth in human lung cancer xenografts and prolongs survival of mice with lipopolysaccharide-induced septic shock. Int Immunopharmacol (2014) 0.85
Characterization of TNF receptor subtype expression and signaling on pulmonary endothelial cells in mice. Am J Physiol Lung Cell Mol Physiol (2011) 0.85
IL-6 adsorption dynamics in hemoadsorption beads studied using confocal laser scanning microscopy. J Biomed Mater Res B Appl Biomater (2010) 0.84
Targeting the "Rising DAMP" during a Francisella tularensis Infection. Antimicrob Agents Chemother (2013) 0.83
Hemolytically active (acylated) alpha-hemolysin elicits interleukin-1beta (IL-1beta) but augments the lethality of Escherichia coli by an IL-1- and tumor necrosis factor-independent mechanism. Infect Immun (1998) 0.83
Regulatory role of GSK-3 β on NF- κ B, nitric oxide, and TNF- α in group A streptococcal infection. Mediators Inflamm (2013) 0.83
Mechanisms involved in the pathogenesis of sepsis are not necessarily reflected by in vitro cell activation studies. Infect Immun (1998) 0.82
Tyrphostin AG 556 improves survival and reduces multiorgan failure in canine Escherichia coli peritonitis. J Clin Invest (1997) 0.82
Transcription factor NF kappa B expression and postsurgical organ dysfunction. Ann Surg (2001) 0.82
The TFPI-2 derived peptide EDC34 improves outcome of gram-negative sepsis. PLoS Pathog (2013) 0.82
The coagulopathy of acute sepsis. Curr Opin Anaesthesiol (2015) 0.82
Disturbances of the hypothalamic-pituitary-adrenal axis and plasma electrolytes during experimental sepsis. Ann Intensive Care (2011) 0.81
RKIP contributes to IFN-γ synthesis by CD8+ T cells after serial TCR triggering in systemic inflammatory response syndrome. J Immunol (2013) 0.81
Increasing the efficacy of anti-inflammatory agents used in the treatment of sepsis. Eur J Clin Microbiol Infect Dis (2003) 0.81
Use of animal model of sepsis to evaluate novel herbal therapies. J Vis Exp (2012) 0.81
Long term outcomes following hospital admission for sepsis using relative survival analysis: a prospective cohort study of 1,092 patients with 5 year follow up. PLoS One (2014) 0.81
Distinctive cytokines as biomarkers predicting fatal outcome of severe Staphylococcus aureus bacteremia in mice. PLoS One (2013) 0.81
Broad spectrum immunomodulation using biomimetic blood cell margination for sepsis therapy. Lab Chip (2016) 0.81
The tyrosine kinase inhibitor tyrphostin AG126 reduces the development of acute and chronic inflammation. Am J Pathol (2000) 0.80
Activity of lipopolysaccharide-binding protein-bactericidal/permeability-increasing protein fusion peptide in an experimental model of Pseudomonas sepsis. Antimicrob Agents Chemother (1995) 0.80
Stem cells in sepsis and acute lung injury. Am J Med Sci (2011) 0.80
Therapies for sepsis. Emerging therapies for sepsis and septic shock. West J Med (1997) 0.79
A dual-role of Gu-4 in suppressing HMGB1 secretion and blocking HMGB1 pro-inflammatory activity during inflammation. PLoS One (2014) 0.78
Bench-to-bedside review: fulfilling promises of the Human Genome Project. Crit Care (2002) 0.78
Template-directed dye-terminator incorporation with fluorescence polarization detection for analysis of single nucleotide polymorphisms implicated in sepsis. J Mol Diagn (2002) 0.78
Is nosocomial infection really the major cause of death in sepsis? Crit Care (2014) 0.77
The immune response: targets for the treatment of severe sepsis. Int J Inflam (2012) 0.77
Immunological evaluation of cytokine and anticytokine immunotherapy in vivo: what have we learnt? Ann Rheum Dis (1999) 0.77
alpha-GlcNAc-1-->2-alpha-glc, the Salmonella homologue of a conserved lipopolysaccharide motif in the Enterobacteriaceae, elicits broadly cross-reactive antibodies. Infect Immun (1998) 0.77
Is boosting the immune system in sepsis appropriate? Crit Care (2014) 0.77
The efficacy and safety of plasma exchange in patients with sepsis and septic shock: a systematic review and meta-analysis. Crit Care (2014) 0.77
Is There NO Treatment For Severe Sepsis? Libyan J Med (2008) 0.75
Dimethyl Cardamonin Exhibits Anti-inflammatory Effects via Interfering with the PI3K-PDK1-PKCα Signaling Pathway. Biomol Ther (Seoul) (2015) 0.75
Bayesian network analysis of multi-compartmentalized immune responses in a murine model of sepsis and direct lung injury. BMC Res Notes (2015) 0.75
The 21st International Symposium on Intensive Care and Emergency Medicine, Brussels, Belgium, 20-23 March 2001. Crit Care (2001) 0.75
Pro/con clinical debate: are steroids useful in the management of patients with septic shock? Crit Care (2002) 0.75
Inhibition of lipogenesis reduces inflammation and organ injury in sepsis. J Surg Res (2015) 0.75
An Agent-Based Model of a Hepatic Inflammatory Response to Salmonella: A Computational Study under a Large Set of Experimental Data. PLoS One (2016) 0.75
TNF and CD28 Signaling Play Unique but Complementary Roles in the Systemic Recruitment of Innate Immune Cells after Staphylococcus aureus Enterotoxin A Inhalation. J Immunol (2016) 0.75
When host defense goes awry: Modeling sepsis-induced immunosuppression. Drug Discov Today Dis Models (2012) 0.75
Role of clinical evaluation committees in sepsis trials: from 'valid cohort' assessment to subgroup analysis. Crit Care (2009) 0.75
Characteristics of CD4(+)CD25(+)Foxp3(+) regulatory T cells in patients with multiple organ dysfunction syndrome. Exp Ther Med (2016) 0.75
Infusion of Bone Marrow Mesenchymal Stem Cells Attenuates Experimental Severe Acute Pancreatitis in Rats. Stem Cells Int (2016) 0.75
Emerging infection and sepsis biomarkers: will they change current therapies? Expert Rev Anti Infect Ther (2016) 0.75
Anti-TNFα Therapy in Inflammatory Lung Diseases bn. Pharmacol Ther (2017) 0.75
Cytokine storm and sepsis disease pathogenesis. Semin Immunopathol (2017) 0.75
Tularemia as a biological weapon: medical and public health management. JAMA (2001) 13.23
Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis (1999) 10.30
The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA (1995) 9.54
Botulinum toxin as a biological weapon: medical and public health management. JAMA (2001) 9.18
Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA (2000) 8.45
Anthrax as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA (1999) 7.06
Hospital-acquired candidemia. The attributable mortality and excess length of stay. Arch Intern Med (1988) 6.78
Response of man to infection with Vibrio cholerae. I. Clinical, serologic, and bacteriologic responses to a known inoculum. J Infect Dis (1974) 6.38
Nosocomial bloodstream infection in critically ill patients. Excess length of stay, extra costs, and attributable mortality. JAMA (1994) 6.11
Epidemiology of nosocomial infections caused by methicillin-resistant Staphylococcus aureus. Ann Intern Med (1982) 5.46
Comparative efficacy of alternative hand-washing agents in reducing nosocomial infections in intensive care units. N Engl J Med (1992) 5.28
Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med (1997) 4.86
Strategies to Prevent and Control the Emergence and Spread of Antimicrobial-Resistant Microorganisms in Hospitals. A challenge to hospital leadership. JAMA (1996) 4.80
Vancomycin-resistant Enterococcus faecium bacteremia: risk factors for infection. Clin Infect Dis (1995) 4.36
Coagulase-negative staphylococcal bacteremia. Mortality and hospital stay. Ann Intern Med (1989) 4.23
Enhanced isolation of Mycoplasma pneumoniae from throat washings with a newly-modified culture medium. J Infect Dis (1979) 4.15
Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group. Lancet (1998) 4.05
Systemic inflammatory response syndrome, sepsis, severe sepsis and septic shock: incidence, morbidities and outcomes in surgical ICU patients. Intensive Care Med (1995) 3.75
Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. Clin Infect Dis (2001) 3.75
Weaning from mechanical ventilation. Eur Respir J (2007) 3.59
National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. SCOPE Participant Group. Surveillance and Control of Pathogens of Epidemiologic. Diagn Microbiol Infect Dis (1998) 3.58
Vancomycin-resistant Staphylococcus aureus: perspectives on measures needed for control. Ann Intern Med (1996) 3.53
A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group. JAMA (1991) 3.25
Spectrum of hantavirus infection: hemorrhagic fever with renal syndrome and hantavirus pulmonary syndrome. Annu Rev Med (1999) 3.24
Elimination of coincident Staphylococcus aureus nasal and hand carriage with intranasal application of mupirocin calcium ointment. Ann Intern Med (1991) 3.24
Methicillin-resistant Staphylococcus aureus: introduction and spread within a hospital. Ann Intern Med (1980) 3.20
Risk factors for candidemia in Neonatal Intensive Care Unit patients. The National Epidemiology of Mycosis Survey study group. Pediatr Infect Dis J (2000) 3.13
Association of slime with pathogenicity of coagulase-negative staphylococci causing nosocomial septicemia. J Clin Microbiol (1985) 3.13
Learning and memory difficulties after environmental exposure to waterways containing toxin-producing Pfiesteria or Pfiesteria-like dinoflagellates. Lancet (1998) 3.03
The role of 'no-touch' automated room disinfection systems in infection prevention and control. J Hosp Infect (2012) 2.97
Risk factors for hospital-acquired candidemia. A matched case-control study. Arch Intern Med (1989) 2.97
National surveillance of nosocomial blood stream infection due to Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. Diagn Microbiol Infect Dis (1998) 2.94
Nosocomial bloodstream infections. Secular trends in rates, mortality, and contribution to total hospital deaths. Arch Intern Med (1995) 2.86
Transmission of rhinovirus colds by self-inoculation. N Engl J Med (1973) 2.80
Growth of continental-scale metro-agro-plexes, regional ozone pollution, and world food production. Science (1994) 2.76
Characterization of the sequence of colonization and nosocomial candidemia using DNA fingerprinting and a DNA probe. J Clin Microbiol (1990) 2.72
Efficient detection and long-term persistence of the carriage of methicillin-resistant Staphylococcus aureus. Clin Infect Dis (1994) 2.67
Microbiological factors influencing the outcome of nosocomial bloodstream infections: a 6-year validated, population-based model. Clin Infect Dis (1997) 2.67
National epidemiology of mycoses survey (NEMIS): variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units. Clin Infect Dis (1999) 2.63
National epidemiology of mycoses survey: a multicenter study of strain variation and antifungal susceptibility among isolates of Candida species. Diagn Microbiol Infect Dis (1998) 2.56
Cervical manipulation. JAMA (1981) 2.52
A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study Group. Crit Care Med (1995) 2.48
The emergence of methicillin-resistant Staphylococcus aureus. Ann Intern Med (1982) 2.32
Long-term survival and function after suspected gram-negative sepsis. JAMA (1995) 2.27
Nosocomial bloodstream infections caused by Acinetobacter species in United States hospitals: clinical features, molecular epidemiology, and antimicrobial susceptibility. Clin Infect Dis (2000) 2.22
Investigation of the sequence of colonization and candidemia in nonneutropenic patients. J Clin Microbiol (1994) 2.22
Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis (2001) 2.19
The epidemiology of intravenous vancomycin usage in a university hospital. A 10-year study. JAMA (1993) 2.18
Methicillin-resistant Staphylococcus aureus: microbiologic characteristics, antimicrobial susceptibilities, and assessment of virulence of an epidemic strain. J Infect Dis (1981) 2.12
Myxedema-associated cardiogenic shock treated with intravenous triiodothyronine. Ann Intern Med (1992) 2.11
Handwashing compliance by health care workers: The impact of introducing an accessible, alcohol-based hand antiseptic. Arch Intern Med (2000) 2.10
Importance of pre-existing co-morbidities for prognosis of septicemia in critically ill patients. Intensive Care Med (1993) 2.05
Septic shock: an analysis of outcomes for patients with onset on hospital wards versus intensive care units. Crit Care Med (1998) 2.04
Selective inhibition of vaccinia virus by the antibiotic rifampicin. Nature (1969) 2.01
Smallpox vaccination for investigators using vaccinia recombinants. Lancet (1989) 2.00
Vancomycin-resistant enterococcal bacteremia: natural history and attributable mortality. Clin Infect Dis (1996) 1.99
Hospital stay and mortality attributed to nosocomial enterococcal bacteremia: a controlled study. Am J Infect Control (1989) 1.98
Methicillin-resistant staphylococcus aureus and community-acquired pneumonia: an evolving relationship. Clin Infect Dis (2012) 1.97
Nosocomial enterococcal blood stream infections in the SCOPE Program: antimicrobial resistance, species occurrence, molecular testing results, and laboratory testing accuracy. SCOPE Hospital Study Group. Diagn Microbiol Infect Dis (1997) 1.95
Postoperative wound infection: a controlled study of the increased duration of hospital stay and direct cost of hospitalization. Ann Surg (1977) 1.95
The significance of nasal carriage of Staphylococcus aureus and the incidence of postoperative wound infection. J Hosp Infect (1995) 1.94
Sepsis in cirrhosis: report on the 7th meeting of the International Ascites Club. Gut (2005) 1.93
The International Collaborative Study of Maternal Phenylketonuria: status report 1998. Eur J Pediatr (2000) 1.91
Managing antibiotic resistance. N Engl J Med (2000) 1.90
Relation between surgical volume and incidence of postoperative wound infection. N Engl J Med (1981) 1.87
Associated mortality and clinical characteristics of nosocomial Pseudomonas maltophilia in a university hospital. J Clin Microbiol (1986) 1.84
Epidemiology of infections due to Pseudomonas aeruginosa. Rev Infect Dis (1987) 1.83
Comparison of protective effect of neutralizing antibody in serum and nasal secretions in experimental rhinovirus type 13 illness. Am J Epidemiol (1969) 1.82
Noninvasive positive pressure ventilation via face mask. First-line intervention in patients with acute hypercapnic and hypoxemic respiratory failure. Chest (1996) 1.80
Comparative evaluation of an automated ribotyping system versus pulsed-field gel electrophoresis for epidemiological typing of clinical isolates of Escherichia coli and Pseudomonas aeruginosa from patients with recurrent gram-negative bacteremia. Diagn Microbiol Infect Dis (1996) 1.78
Nosocomial urinary tract infections due to enterococcus. Ten years' experience at a university hospital. Arch Intern Med (1986) 1.77
Successful treatment of adults with severe Hantavirus pulmonary syndrome with extracorporeal membrane oxygenation. Crit Care Med (1998) 1.76
Rickettsialpox in a New York City hospital, 1980 to 1989. N Engl J Med (1994) 1.75
Hospital-acquired bloodstream infections with Staphylococcus epidermidis. Review of 100 cases. Am J Med (1984) 1.74
Inducible amp C beta-lactamase producing gram-negative bacilli from blood stream infections: frequency, antimicrobial susceptibility, and molecular epidemiology in a national surveillance program (SCOPE). Diagn Microbiol Infect Dis (1997) 1.73
Anti-endotoxin monoclonal antibodies--a second look. N Engl J Med (1992) 1.73
Purpose of quality standards for infectious diseases. Infectious Diseases Society of America. Clin Infect Dis (1994) 1.70
Randomized double-blind, multicenter study of prostaglandin E1 in patients with the adult respiratory distress syndrome. Prostaglandin E1 Study Group. Chest (1989) 1.67
Liposomal prostaglandin E1 (TLC C-53) in acute respiratory distress syndrome: a controlled, randomized, double-blind, multicenter clinical trial. TLC C-53 ARDS Study Group. Crit Care Med (1999) 1.65
Coronavirus infections in military recruits. Three-year study with coronavirus strains OC43 and 229E. Am Rev Respir Dis (1974) 1.62
Gastric feeding with erythromycin is equivalent to transpyloric feeding in the critically ill. Crit Care Med (2001) 1.62
Plasma tumor necrosis factor levels in patients with presumed sepsis. Results in those treated with antilipid A antibody vs placebo. JAMA (1989) 1.59
Influence of in vitro susceptibility testing conditions on the anti-candidal activity of LY121019. Diagn Microbiol Infect Dis (1988) 1.57
Emergence of coagulase negative staphylococci as major nosocomial bloodstream pathogens. Infect Control (1987) 1.57
Quality standard for antimicrobial prophylaxis in surgical procedures. Infectious Diseases Society of America. Clin Infect Dis (1994) 1.56
Comparative in vitro activity of the new quinolone sparfloxacin (CI-978, AT-4140) against nosocomial gram-negative bloodstream isolates. Eur J Clin Microbiol Infect Dis (1990) 1.56
Outbreak of keratitis presumed to be caused by Acanthamoeba. Am J Ophthalmol (1996) 1.55
Recent trends in employer-sponsored health insurance coverage: are bad jobs getting worse? J Health Econ (2000) 1.55
Maternal phenylketonuria syndrome: congenital heart defects, microcephaly, and developmental outcomes. J Pediatr (2000) 1.54
Hospital specificity, region specificity, and fluconazole resistance of Candida albicans bloodstream isolates. J Clin Microbiol (1998) 1.53
The use of biotyping and DNA fingerprinting in typing Candida albicans from hospitalized patients. Diagn Microbiol Infect Dis (1991) 1.52
Removal of nosocomial pathogens from the contaminated glove. Implications for glove reuse and handwashing. Ann Intern Med (1988) 1.51
In vitro activities of teichomycin, fusidic acid, flucloxacillin, fosfomycin, and vancomycin against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (1984) 1.51
Hospital-acquired pneumonia. Attributable mortality and morbidity. Am J Epidemiol (1989) 1.48
Nosocomial pneumonia in patients having bone marrow transplant. Attributable mortality and risk factors. Cancer (1992) 1.47